| Type 1 diabetes in adults: diagnosis and management | NG17 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| SecurAcath for securing percutaneous catheters | MTG34 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Stockholm3 for prostate cancer screening | MIB303 | | |
| Bioresorbable stent implantation to treat coronary artery disease | IPG732 | | |
| Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | IPG733 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| PLGF-based testing to help diagnose suspected preterm pre-eclampsia | DG49 | | |
| Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | IPG730 | | |
| Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | IPG731 | | |
| Melanoma: assessment and management | NG14 | | |
| Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
| Fever in under 5s | QS64 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Urinary tract infection in children and young people | QS36 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | MTG9 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| ProciseDx point-of-care platform for inflammatory bowel disease | MIB302 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
| Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
| RespiraSense for continuously monitoring respiratory rate | MIB299 | | |
| Cyanoacrylate glue for hernia mesh fixation | MIB301 | | |
| MiraQ for assessing graft flow during coronary artery bypass graft surgery | MTG8 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Vertebral body tethering for idiopathic scoliosis in children and young people | IPG728 | | |
| Nerve graft for corneal denervation | IPG729 | | |
| Depression in adults: treatment and management | NG222 | | |
| Type 2 diabetes in adults: management | NG28 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Multiple sclerosis in adults: management | NG220 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Reducing sexually transmitted infections | NG221 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Preterm labour and birth | NG25 | | |